原发性肝癌转化治疗研究进展

江杰; 胡宗强; 陈刚; 徐源通; 褚光

doi:10.3969/j.issn.1001-5256.2020.08.042

原发性肝癌转化治疗研究进展

DOI: 10.3969/j.issn.1001-5256.2020.08.042

昆明医科大学附属甘美医院暨昆明市第一人民医院肝胆外科

基金项目:

云南省教育厅科学研究基金(2019Y0367)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1097
- HTML全文浏览量: 82
- PDF下载量: 186
- 被引次数: 0
出版历程
- 出版日期: 2020-08-20

Research advances in conversion therapy for primary liver cancer

Department of Hepatobiliary Surgery, The Affiliated Ganmei Hospital of Kunming Medical University & The First People’s Hospital of Kunming

Research funding:

摘要

摘要:
根治性肝切除及肝移植术是改善原发性肝癌远期预后的最佳选择,然而我国大部分肝癌患者确诊时已丧失手术治疗机会。因此,转化治疗成为提高中晚期肝癌患者生存率的研究热点。简述了肝癌转化治疗的评估内容,并归纳了目前不可切除性肝癌的转化治疗方案。随着对原发性肝癌及个体化治疗的进一步了解,精准医疗联合多学科诊疗团队制定出个体化的转化治疗方案,认为能够有效提高中晚期肝癌患者手术切除率及治疗效果,改善远期预后。
- 肝肿瘤 /
- 治疗学 /
- 治疗结果
Abstract:
Radical hepatectomy and liver transplantation are the best choices to improve the long-term prognosis of patients with primary liver cancer;however,most of the patients in China have lost the opportunity for surgical treatment at the time of confirmed diagnosis.Therefore,conversion therapy has become a research hotspot in improving the survival rate of patients with advanced liver cancer.This article briefly describes the evaluation of conversion therapy for liver cancer and summarizes the current conversion treatment regimens for unresectable liver cancer.With the deepening of the understanding of primary liver cancer and individualized treatment,the group of precise treatment combined with multidisciplinary diagnosis and treatment develops the regimens for individualized conversion therapy,which is considered to effectively improve the surgical resection rate,treatment outcome,and long-term prognosis of patients with advanced liver cancer.
- liver neoplasms /
- therapeutics /
- treatment outcome

HTML全文

参考文献(30)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] ZHENG RS,ZENG HM,ZHANG SW,et al. Estimates of cancer incidence and mortality in China,2013[J]. Chin J Cancer,2017,36(1):384-389.

[3] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.

[4] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.

[5] HEIMBACH JK,KULIK LM,FINN RS,et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2018,67(1):358-380.

[6] KHAN AS,GARCIA-AROZ S,ANSARI MA,et al. Assessment and optimization of liver volume before major hepatic resection:Current guidelines and a narrative review[J]. Int J Surg,2018,52:74-81.

[7] XU JM,CHANG WJ,JIAN M. New progression and direction of translational medicine on colorectal cancer[J]. Chin J Dig Surg,2018,17(4):357-361.(in Chinese)许剑民，常文举，鉴谧．结直肠癌转化医学领域的现状与展望[J]．中华消化外科杂志，2018,17(4):357-361.

[8] Organ Transplantation Branch,Chinese Medical Doctor Association; Chinese Society of Organ Transplantation,Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma(2018)[J]. J Clin Hepatol,2019,35(2):275-280.(in Chinese)中国医师协会器官移植医师分会，中华医学会器官移植学分会．中国肝癌肝移植临床实践指南(2018版)[J]．临床肝胆病杂志，2019,35(2):275-280.

[9] Chinese Society of Liver Cancer,Chinese Medical Doctor Association. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus(2018)[J]. J Clin Hepatol,2019,35(4):737-743.(in Chinese)中国医师协会肝癌专业委员会．肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]．临床肝胆病杂志，2019,35(4):737-743.

[10] KULIK L,HEIMBACH JK,ZAIEM F,et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation:A systematic review and meta-analysis[J]. Hepatology,2018,67(1):381-400.

[11] KIM Y,STAHL CC,MAKRAMALLA A,et al. Downstaging therapy fol owed by liver transplantation for hepatocellular carcinoma beyond Milan criteria[J]. Surgery,2017,162(6):1250-1258.

[12] ORLACCHIO A,CHEGAI F,MEROLLA S,et al. Downstaging disease in patients with hepatocellular carcinoma outside upto-seven criteria:Strategies using degradable starch microspheres transcatheter arterial chemo-embolization[J]. World J Hepatol,2015,7(12):1694-1700.

[13] ZHANG Y,HUANG G,WANG Y,et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization?Ten years of experience[J]. Oncologist,2016,21(12):1442-1449.

[14] ZHAO M. Hepatic arterial infusion chemotherapy in the era of precise medicine[J]. J Sun Yat-Sen Univ(Medical Sciences),2019,40(5):648-656.(in Chinese)赵明．精准医疗时代背景下的肝动脉灌注化疗[J]．中山大学学报(医学科学版)，2019,40(5):648-656.

[15] HE MK,LE Y,LI QJ,et al. Hepatic artery infusion chemotherapy using m FOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma:A prospective non-randomized study[J]. Chin J Cancer,2017,36(1):83.

[16] LEE BH,LEE DS,CHO CW,et al. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A[J]. World J Surg Oncol,2019,17(1):143.

[17] NAGAMATSU H,SUMIE S,NIIZEKI T,et al. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma:Multicenter phase II study[J]. Cancer Chemother Pharmacol,2016,77(2):243-250.

[18] TAN YH,SHANG YY,ZHANG T,et al. Current status and perspectives of multimodality therapy for hepatocellular carcinoma[J]. J Clin Hepatol,2019,35(8):1858-1860.(in Chinese)谭运华，商阳阳，张涛，等．肝细胞癌综合治疗的现状和前景[J]．临床肝胆病杂志，2019,35(8):1858-1860.

[19] CAI HH,SHAO JC,HU ZM,et al. Laparoscopic hepatectomy combined with radiofrequency ablation for management of liver cancer in difficult place[J]. Chin J Gen Surg,2019,34(5):417-420.(in Chinese)蔡涵晖，邵洁超，胡智明，等．腹腔镜肝切除联合射频消融术在难治性肝癌中的临床应用[J]．中华普通外科杂志，2019,34(5):417-420.

[20] LI Y. The value of hepatic lobectomy combined with ultrasound guided radiofrequency ablation in the treatment of multiple liver cancer[J]. J Hepatobiliary Surg,2018,26(1):46-48.(in Chinese)李岩．肝叶切除联合术中射频消融治疗多发性肝癌的价值分析[J]．肝胆外科杂志，2018,26(1):46-48.

[21] ZHANG YB,HONG DF,FAN XM,et al. Percutaneous microwave/radiofrequency ablation liver partition and portal vein embolization for planned hepatectomy for colorectal liver metastases with insufficient future liver remnant[J]. Chin J Oncol,2017,39(7):545-546.(in Chinese)张远标，洪德飞，范小明，等．经皮微波或射频消融肝实质分隔联合门静脉栓塞计划性肝切除术治疗剩余肝体积不足结肠癌肝转移的探索性研究[J]．中华肿瘤杂志，2017,39(7):545-546.

[22] PRACHT M,EDELINE J,LENOIR L,et al. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization:Preliminary results[J]. Int J Hepatol,2013,2013:827649.

[23] ASSALINO M,TERRAZ S,GRAT M,et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion-a multi-center retrospective cohort study[J]. Transpl Int,2020,33(5):567-575.

[24] BRUIX J,CHENG AL,MEINHARDT G,et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma:Analysis of two phase III studies[J]. J Hepatol,2017,67(5):999-1008.

[25] KUDO M,MATILLA A,SANTORO A,et al. Nivolumab in patients with Child-Pugh A advanced hepatocellular carcinoma in the Check-Mate 040 study[C]. San Francisco:2018 Annual Liver Meeting,2018:Abstract LB-2.

[26] KASEB AO,VENCE L,BLANDO J,et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma[J]. Cancer Immunol Res,2019,7(9):1390-1395.

[27] DENG L,JIANG YL,WU WQ,et al. Analysis of clinical efficacy of FOLFOX4 chemotherapy for primary hepatocellular carcinoma and prognostic factors[J]. Pract J Cancer,2016,31(12):1980-1982,1986.(in Chinese)邓兰，蒋益兰，吴文清，等．FOLFOX4方案化疗对原发性肝癌患者的临床效果及预后影响因素分析[J]．实用癌症杂志，2016,31(12):1980-1982,1986.

[28] KASEB AO,SHINDOH J,PATT YZ,et al. Modified cisplatin/interferonα-2b/doxorubicin/5-fluorouracil(PIAF)chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate,resectability,and survival of initially unresectable hepatocellular carcinoma[J]. Cancer,2013,119(18):3334-3342.

[29] LEUNG TW,PATT YZ,LAU WY,et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma[J]. Clin Cancer Res,1999,5(7):1676-1681.

[30] FARGES O,BELGHITI J,KIANMANESH R,et al. Portal vein embolization before right hepatectomy:Prospective clinical trial[J]. Ann Surg,2003,237(2):208-217.

施引文献

资源附件(0)

访问统计